The regulatory setback occurred on February 13, 2026, when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine. Federal regulators declined to approve the company's new drug application, citing significant uncertainties that require further clinical evidence. This decision effectively stalled the progress of the bitopertin program, leading to the sharp decline in shareholder value.

Investors who purchased securities in the company are currently being invited to join a prospective class action. Rosen Law is organizing the litigation under a contingency fee arrangement, meaning participants would not incur out-of-pocket costs. Those seeking to participate in the investigation can contact attorney Phillip Kim to discuss the legal process and potential recovery of losses.